R1 Therapeutics expands Series A financing to $80.5 million with new investment from Samsara BioCapital. The funds will advance their Phase 2b program for hyperphosphatemia in patients with chronic kidney disease.
PRIVATESep 30, 2026
Amount Raised
$80.5 Million
Round Type
Series A
BiotechnologyHealth CareTherapeutics
Investors
U.S. Renal CareSNMA CapitalCurie.BioF PrimeDaVita Venture GroupAbingworthSamsara Biocapital
Description
R1 Therapeutics, a biopharmaceutical company focused on kidney disease therapies, has expanded its Series A financing to $80.5 million. This expansion includes new investment from Samsara BioCapital, joining other notable investors. The raised funds will support the development of R1's lead asset, AP306, in a global Phase 2b trial. The trial aims to address hyperphosphatemia in patients on dialysis, with topline data expected in early 2027.
Company Information
Company
R1 Therapeutics
About
R1 Therapeutics is a biotechnology company focused on developing innovative therapeutics. The company leverages advanced technologies to create treatments that address unmet medical needs. Their approach aims to enhance patient outcomes and streamline the drug development process. With a commitment to scientific excellence, R1 Therapeutics strives to bring novel therapies to market.
Fundz sees it the moment R1 Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
